Welcome to the OMA Blog

Metabolic bariatric surgery (MBS) is an effective intervention for treating pediatric obesity, but access remains limited. This review examines the latest guidelines from the professional organizations including the American Academy of Pediatrics (AAP) and the American Society for Metabolic and Bariatric Surgery, highlighting patient selection, surgical options and the role of telehealth in expanding care for children and adolescents with severe obesity.

Deepen your understanding of lipodystrophy—from symptoms and diagnosis to treatment strategies—with our comprehensive guide.

Hypertension in patients with obesity is on the rise. Learn the key risk factors and how to manage them effectively.

This article reveals crucial insights into childhood obesity as major risk factor for heart disease, highlighting hidden dangers and essential strategies every parent and caregiver should know.

January 27, 2025 – The Obesity Medicine Association (OMA) acknowledges the Lancet Commission’s effort to refine obesity diagnosis with the introduction of “preclinical” and “clinical” obesity classifications. However, we express significant concerns about the potential unintended consequences of this framework, which risks redefining obesity from a disease to merely a risk factor, undermining decades of progress in recognizing obesity as a chronic, progressive and relapsing multifactorial disease.

Explore the milestones, innovations, and advocacy efforts that have shaped the field, from early beginnings to modern breakthroughs. Join us in honoring the past and advancing the future of obesity medicine.

This article explores dietary interventions for obesity, emphasizing personalized nutrition plans, evidence-based culinary medicine, and sustainable diets like Mediterranean and DASH. It highlights calorie reduction, meal timing, and weight maintenance strategies.

Explore the relationship between obesity and exercise, including current guidelines, challenges, and benefits beyond weight loss.

Risk of major depression, anxiety, and suicidal ideation or attempts were increased in adults who took glucagon like peptide-1 receptor agonist medication for type 2 diabetes or obesity compared with propensity score matched adults with obesity who did not take this medication.